Pollen Allergy
7
2
3
3
Key Insights
Highlights
Success Rate
75% trial completion
Treatment Research
13 treatments under study, led by Mg0130000
Research Leaders
16 sponsors active, led by Mabylon AG
Related Conditions
Often studied with 7 related conditions
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
14.3%
1 terminated out of 7 trials
75.0%
-11.6% vs benchmark
57%
4 trials in Phase 3/4
0%
0 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 3 completed trials
Clinical Trials (7)
Identification of Allergen-reactive Antibodies in the Blood of Pollen Allergic Patients
Identification of B Regulatory Cells by Flow Cytometry
Impacts of Nitrogen Deposition in the Natural Environment on Pollen Allergy in Belgium
Methylprednisolone Injections Treating Birch Pollen Induced Allergic Rhinitis.
Efficacy and Safety Evaluation for the Treatment of Asthma and Allergic Rhinitis/Rhinoconjunctivitis
Safety and Efficacy of Specific Immunotherapy With an Aluminium Hydroxide-adsorbed Allergoid Preparation of Birch Pollen Allergens
Comparison of the Efficacy and the Safety of Different Schedules of Administration of Sub-lingual Immunotherapy
Research Network
Common Treatments
- Mg01300001
- Immunoreactivity Testing Negative Control1
- Mm09300001
- Mm09mg0130000300001
- Nacl 9 Mgml Injectable Solution1
Active Sponsors
- Mabylon AG1
- BioClever 2005 S.L.1
- Karolinska Institutet1
- prof. dr. Rik Schrijvers1
- Allergopharma GmbH & Co. KG1
Top Investigators
Hull University Teaching Hospitals NHS Trust
Karolinska Institutet
Complejo Hospitalario de Navarra
luigi sacco hospital milano
Related Conditions
- Venom Allergy1
- Allergic Rhinoconjunctivitis1
- Hay Fever1
- Perennial Allergic Rhinitis1
- Allergic Rhinitis1